In a clinical context, immunohistochemistry assessed α-SMA expression in lung adenocarcinoma, indicating a significant correlation between increased α-SMA abundance, elevated lymph node metastasis, and reduced 5-year overall survival (OS) rates in patients (52, 53). Here, ACTA1 is linked to lung adenocarcinoma.